<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02530138</url>
  </required_header>
  <id_info>
    <org_study_id>563</org_study_id>
    <nct_id>NCT02530138</nct_id>
  </id_info>
  <brief_title>The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <brief_summary>
    <textblock>
      Introduction: Currently, Nonalcoholic Fatty Liver Disease (NAFLD) is the most common liver
      disease in the world. The only approved treatment for it is lifestyle modification and weight
      loss; however, there is no evidence for patients with normal or low body mass index (BMI).

      The aim of this study is to evaluate the efficacy of symbiotic supplementation in NAFLD
      patients with normal or low BMI.

      Methods and analysis: In this randomized, double-blind, placebo-controlled clinical trial
      protocol, 21 cases and 21 controls will be individually matched based on age and sex. This 42
      patients with NAFLD will be supplemented twice daily for 28 wk with either a synbiotic or a
      placebo capsule. Both groups will be advised to follow an energy balanced diet and physical
      activity recommendations.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alaninaminotransferase (ALT) (UL)</measure>
    <time_frame>28 weeks</time_frame>
    <description>by biochemical method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hepatic steatosis (cap score)</measure>
    <time_frame>28 weeks</time_frame>
    <description>using transient elastography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI) (kg/m2)</measure>
    <time_frame>28 weeks</time_frame>
    <description>using formula</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Synbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 synbiotic capsules for 28 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltodexterin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two capsules per day for 28 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>synbiotic</intervention_name>
    <description>2 symbiotics capsules per day for 28 weeks</description>
    <arm_group_label>Synbiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 placebo capsules per day for 28 weeks</description>
    <arm_group_label>maltodexterin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 to 70 years

          -  Body Mass Index (BMI) below 25

          -  Serum alaninaminotransferase more than 1.5 fold of upper limit of normal range

          -  Sonographic findings compatible with hepatic steatosis (degree 2 or more)

        Exclusion Criteria:

          -  Diabetes

          -  Taking any kind of antibiotics two weeks before recruitment

          -  History of alcohol consumption

          -  pregnancy or lactation

          -  Professional athletes

          -  Other liver disease (viral/etc)

          -  Use of drugs such as calcium channel blockers, high dose synthetic estrogens,
             methotrexate , amiodarone, steroids, chloroquine, immunosuppressive drugs,
             lipid-lowering agents, metformin and vitamin E

          -  A history of Hypertension, Cardiovascular disease, Pulmonary disease, Renal disease &amp;
             Celiac disease; Cirrhosis

          -  History of Upper GI surgery / Prior surgical procedures such as jejunoileal or
             jejunocolic bypass, gastroplasty

          -  Following program to lose weight in recent 3 mo

          -  A history of hypothyroidism or Cushing's syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Azita Hakmatdost, MD, PhD</last_name>
    <phone>9123065084</phone>
    <email>a_hekmat2000@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NNFTRI clinic</name>
      <address>
        <city>Tehran</city>
        <zip>19435</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azita Hekmatdoost, MD, PhD</last_name>
      <phone>9123065084</phone>
      <email>a_hekmat2000@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Dr Azita Hekmatdoost</investigator_full_name>
    <investigator_title>associate prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

